3,4-methylenedioxymethamphetamine increases susceptiblity to genital herpes simplex virus infection in mice

Journal of Infectious Diseases

Volumn 200, Issue 8, 2009, Pages 1247-1250

  Pennock, Jeffry W ^a   Stegall, Rachael ^a   Bubar, Marcy J ^a   Milligan, Gregg ^a   Cunningham, Kathryn A ^a   Bourne, Nigel ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CHEMOKINE; CYTOKINE;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFECT; FEMALE; GENITAL HERPES; GENITAL SYSTEM; HERPES SIMPLEX VIRUS 2; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CYTOKINES; DISEASE SUSCEPTIBILITY; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; MICE; MICE, INBRED C57BL; MUCOUS MEMBRANE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; VAGINA;

EID: 70349410394     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605891     Document Type: Article

References (15)

1. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: national findings. NSDUH series H-34, DHHS publication SMA 08-4343. Rockville, MD: DHHS, 2008.
2. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 2001; 165:917-928
3. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 1988; 149:159-163
4. Rudnick G, Wall SC. The molecular mechanism of "ecstasy" [3,4methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 1992;89:1817-1821.
5. Colfax G, Guzman R. Club drugs and HIV infection: a review. Clin Infect Dis 2006;42:1463-1469
6. Connor TJ. Methylenedioxymethamphetamine (MDMA, 'ecstasy'): a stressor on the immune system. Immunology 2004; 111:357-367
7. Connor TJ, Harkin A, Kelly JP. Methylenedioxymethamphetamine suppresses production of the proinflammatory cytokine tumor necrosis factor-alpha independent of a beta-adrenoceptor-mediated increase in interleukin-10. J Pharmacol Exp Ther 2005;312:134-143 (Pubitemid 40096462)
8. Nelson DA, Nirmaier JL, Singh SJ, Tolbert MD, Bost KL. Ecstasy (3,4methylenedioxymethamphetamine) limits murine gammaherpesvirus-68 induced monokine expression. Brain Behav Immun 2008; 22: 912-922
9. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-973 (Pubitemid 44285373)
10. Corey L. Herpes simplex virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practices of infectious diseases. 6th ed, vol 2. Philadelphia: Elsevier, 2005:1762-1780
11. Blower S, Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis 2004; 39(Suppl 5):S240-7. (Pubitemid 39447299)
12. Corey L. Synergistic copathogens-HIV-1 and HSV-2. N Engl J Med 2007;356:854-856
13. Bourne N, Milligan GN, Schleiss MR, Bernstein DI, Stanberry LR. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996; 14:1230-1234 (Pubitemid 26388734)
14. Boyle NT, Connor TJ. MDMA ("ecstasy") suppresses the innate IFNgamma response in vivo: a critical role for the anti-inflammatory cytokine IL-10. Eur J Pharmacol 2007;572:228-238
15. Connor TJ, Connelly DB, Kelly JP. Methylenedioxymethamphetamine (MDMA; 'ecstasy') suppresses antigen specific IgG2a and IFN-gamma production. Immunol Lett 2001; 78:67-73.